Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 21st October 2020 from 07:00 AM to 07:00 PM (BST).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 8, 2016
Previous Article Next Article

Identification of a novel BODIPY minihepcidin tool for the high content analysis of ferroportin (SLC40A1) pharmacology

Author affiliations

Abstract

Iron is essential to life and is actively absorbed by enterocytes and secreted into plasma by the iron exporter ferroportin (SLC40A1). Dysregulation of iron homeostasis is a key component of many diseases such as hemochromatosis and beta-thalassemia. Ferroportin is the only known iron exporter protein, and as such is an important therapeutic target. To-date, modulators of ferroportin activity have shown promise in pre-clinical models, with recent screening assays enabling screening in a high throughput “loss of signal” format. Herein, we describe the design and synthesis of a novel BODIPY-labelled minihepcidin peptide to enable the high content analysis of ferroportin (SLC40A1) pharmacology, and the high throughput screening of compounds in a “gain of signal” assay format.

Graphical abstract: Identification of a novel BODIPY minihepcidin tool for the high content analysis of ferroportin (SLC40A1) pharmacology

Back to tab navigation

Supplementary files

Article information


Submitted
11 May 2016
Accepted
03 Jun 2016
First published
08 Jun 2016

Med. Chem. Commun., 2016,7, 1564-1571
Article type
Research Article

Identification of a novel BODIPY minihepcidin tool for the high content analysis of ferroportin (SLC40A1) pharmacology

Sarah. E. Skerratt, S. Humphreys, R. Ferreira, C. Jorgensen, J. Warmus, L. Zhao, X. Tong and S. A. Nickolls, Med. Chem. Commun., 2016, 7, 1564
DOI: 10.1039/C6MD00260A

Search articles by author

Spotlight

Advertisements